Share

Today, we would like to share with you the talk given by Kelsey Moody, CEO of Biotech Company Ichor, at the recent Ending Age-Related Diseases: Investment Prospects & Advances in Research conference in New York City. In this talk, Kelsey discusses Ichor’s protein engineering platform, how Ichor has used it, and Ichor’s plans for using it to discover new classes of drugs for age-related diseases.

Kelsey is a process-oriented biotechnology executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, he has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated contract research organization that focuses on preclinical research services for aging pathways. Proceeds from this work are used to self-fund R&D initiatives that constitute Ichor’s portfolio companies in enzyme therapy (Lysoclear, Inc.), small molecule drug discovery (Antoxerene, Inc.), and protein engineering (RecombiPure, Inc.) Kelsey has received graduate-level training in medicine, business, and laboratory research.

Kelsey is very much a rising star in the field, and we suspect that he may become one of the most important people in the development of therapies in the next few years, judging by his impressive track record to date. We are watching the work that Ichor and its portfolio companies are doing with great interest, and we are grateful to Kelsey for giving this talk, for sponsoring the conference, and for continuing to be a driving force for progress against age-related diseases.

About the author

Steve Hill

As a scientific writer and a devoted advocate of healthy longevity and the technologies to promote them, Steve has provided the community with hundreds of educational articles, interviews, and podcasts, helping the general public to better understand aging and the means to modify its dynamics. His materials can be found at H+ Magazine, Longevity reporter, Psychology Today and Singularity Weblog. He is a co-author of the book “Aging Prevention for All” – a guide for the general public exploring evidence-based means to extend healthy life (in press).
  1. August 21, 2018

    I think a huge market could be a topical RPTag to il4r which is targeted by Sanofi’s Durpexent antibody for eczema.

Write a comment:

*

Your email address will not be published.

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD